Laurion Capital Management’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-3,543
Closed -$63.7K 536
2023
Q3
$63.7K Sell
3,543
-4,083
-54% -$160K ﹤0.01% 460
2023
Q2
$480K Hold
7,626
﹤0.01% 424
2023
Q1
$379K Hold
7,626
﹤0.01% 356
2022
Q4
$219K Hold
7,626
﹤0.01% 380
2022
Q3
$360K Hold
7,626
﹤0.01% 415
2022
Q2
$330K Hold
7,626
0.01% 363
2022
Q1
$419K Sell
7,626
-168
-2% -$9.44K 0.01% 392
2021
Q4
$590K Hold
7,794
0.01% 401
2021
Q3
$700K Sell
7,794
-508
-6% -$54.3K ﹤0.01% 545
2021
Q2
$1.05M Hold
8,302
0.01% 434
2021
Q1
$1.26M Hold
8,302
0.01% 472
2020
Q4
$2.59M Buy
+8,302
New +$3.09M 0.02% 321

Other funds holding DMRA

Laurion Capital Management's DMRA Position: Q4 2023 in Review

Laurion Capital Management sold out of Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q4 2023, closing a stake of 3,543 shares — an estimated $63.7K sold.

Laurion Capital Management first reported a position in DMRA in Q4 2020 and held it in 12 quarters. The position peaked at $2.59M in Q4 2020. 21 funds tracked by Wall St. Rank hold DMRA as of Q4 2023.

  • Laurion Capital Management reported no remaining Damora Therapeutics, Inc. Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Laurion Capital Management sold 3,543 Damora Therapeutics, Inc. Ordinary Shares shares in Q4 2023, an estimated $63.7K.
  • Laurion Capital Management first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q4 2020 and held it in 12 quarters.
  • Laurion Capital Management's Damora Therapeutics, Inc. Ordinary Shares position peaked at $2.59M in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q4 2023.

Based on Laurion Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.